| Title: | Effect of biological therapy on symptom burden and functional disability in patients with migraine : a before-and-after analysis |
|---|
| Authors: | ID Kalač, Albina (Author)
ID Fabjan, Andrej (Author)
ID Žibert, Janez (Author)
ID Kamenšek, Tina (Author) |
|---|
| Files: |  PDF - Presentation file, download (409,79 KB)
MD5: 2BB9C12AD035AC58FC48FC9A85C679BC
 URL - Source URL, visit https://reference-global.com/article/10.2478/sjph-2026-0005
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  NIJZ - National Institute of Public Health
 UKC LJ - Ljubljana University Medical Centre
|
|---|
| Abstract: | Introduction
This study aims to assess the effectiveness of biological therapies in reducing migraine-related symptom
burden and functional disability, including reductions in monthly migraine days, pain intensity, and analgesic
consumption, among patients with migraine in Slovenia.
Methods
This retrospective study analysed 92 adult patients with migraine receiving prophylactic biological treatment
at the University Medical Centre Ljubljana. Average number of monthly migraine days (MMD), average analgesic
consumption, pain intensity (VAS), and functional disability score (MIDAS) were collected before treatment and
after 3 and 12 months. Statistical analysis involved the Friedman test to assess changes over time, followed by
Wilcoxon tests with Bonferroni correction for post hoc comparisons.
Results
83 patients completed 12 months of treatment. Significant reductions (p < 0.001) were observed in MMD (median
10 vs. 2 days), analgesic consumption, VAS scores (median 8 vs. 4), and MIDAS scores after 3 months (median 19
vs. 2), sustained at 12 months. Treatment discontinuation occurred in 9 patients due to inefficacy or side effects.
Most patients tolerated biologics well, with mild adverse effects reported.
Conclusions
Biological therapies significantly reduced migraine-related symptom burden and functional disability, including
decreases in migraine frequency, pain intensity, and analgesic use, in a Slovenian migraine cohort. These findings
support the use of biologics as effective and safe options for migraine prevention in real-world clinical practice. |
|---|
| Keywords: | monoclonal antibodies, neurology, disability evaluation, preventive treatment |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Article acceptance date: | 20.08.2025 |
|---|
| Year of publishing: | 2026 |
|---|
| Number of pages: | str. 34-40 |
|---|
| Numbering: | Vol. 65, no. 1 |
|---|
| PID: | 20.500.12556/DiRROS-30102  |
|---|
| UDC: | 616.857 |
|---|
| ISSN on article: | 0351-0026 |
|---|
| DOI: | 10.2478/sjph-2026-0005 |
|---|
| COBISS.SI-ID: | 270641411 |
|---|
| Note: | Besedilo v angl.;
|
|---|
| Pub. date in DiRROS: | 15.06.2026 |
|---|
| Views: | 300 |
|---|
| Downloads: | 196 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
